Evaluation of production protocols for the generation of NY-ESO-1-specific T cells
NY-ESO-1-specific T cells have shown promising activity in the treatment of soft tissue sarcoma (STS). However, standardized protocols for their generation are limited. Particularly, cost-effectiveness considerations of cell production protocols are of importance for conducting clinical studies. In...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
14 January 2021
|
| In: |
Cells
Year: 2021, Volume: 10, Issue: 1 |
| ISSN: | 2073-4409 |
| DOI: | 10.3390/cells10010152 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cells10010152 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2073-4409/10/1/152 |
| Author Notes: | Wenjie Gong, Lei Wang, Sophia Stock, Ming Ni, Maria-Luisa Schubert, Brigitte Neuber, Christian Kleist, Angela Hückelhoven-Krauss, Depei Wu, Carsten Müller-Tidow, Anita Schmitt, Hiroshi Shiku, Michael Schmitt and Leopold Sellner |
| Summary: | NY-ESO-1-specific T cells have shown promising activity in the treatment of soft tissue sarcoma (STS). However, standardized protocols for their generation are limited. Particularly, cost-effectiveness considerations of cell production protocols are of importance for conducting clinical studies. In this study, two different NY-ESO-1-specific T cell production protocols were compared. Major differences between protocols 1 and 2 include culture medium, interleukin-2 and retronectin concentrations, T cell activation strategy, and the transduction process. NY-ESO-1-specific T cells generated according to the two protocols were investigated for differences in cell viability, transduction efficiency, T cell expansion, immunophenotype as well as functionality. NY-ESO-1-specific T cells showed similar viability and transduction efficiency between both protocols. Protocol 1 generated higher absolute numbers of NY-ESO-1-specific T cells. However, there was no difference in absolute numbers of NY-ESO-1-specific T cell subsets with less-differentiated phenotypes accounting for efficient in vivo expansion and engraftment. Furthermore, cells generated according to protocol 1 displayed higher capacity of TNF-α generation, but lower cytotoxic capacities. Overall, both protocols provided functional NY-ESO-1-specific T cells. However, compared to protocol 1, protocol 2 is advantageous in terms of cost-effectiveness. Cell production protocols should be designed diligently to achieve a cost-effective cellular product for further clinical evaluation. |
|---|---|
| Item Description: | Gesehen am 04.03.2021 |
| Physical Description: | Online Resource |
| ISSN: | 2073-4409 |
| DOI: | 10.3390/cells10010152 |